Compare CRNX & DOCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | DOCS |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2018 | 2021 |
| Metric | CRNX | DOCS |
|---|---|---|
| Price | $83.73 | $20.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $76.75 | $45.50 |
| AVG Volume (30 Days) | ★ 6.8M | 2.9M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.98 |
| Revenue | $1,039,000.00 | ★ $644,863,000.00 |
| Revenue This Year | $720.10 | $15.08 |
| Revenue Next Year | $184.67 | $8.83 |
| P/E Ratio | ★ N/A | $20.87 |
| Revenue Growth | N/A | ★ 13.05 |
| 52 Week Low | $25.83 | $17.15 |
| 52 Week High | $84.00 | $76.51 |
| Indicator | CRNX | DOCS |
|---|---|---|
| Relative Strength Index (RSI) | 92.07 | 43.34 |
| Support Level | $33.50 | $20.55 |
| Resistance Level | N/A | $21.07 |
| Average True Range (ATR) | 0.18 | 0.85 |
| MACD | -0.10 | -0.17 |
| Stochastic Oscillator | 53.51 | 15.43 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.